The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain
on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral …

Since being declared a global pandemic by the World Health Organization WHO),
Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory …

With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and
limited vaccine availability for the general population in most countries, the monoclonal …

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of
SARS-CoV-2 variants raised concerns about these therapies' efficacy and long-term …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …

This article is made available for historical review, monoclonal antibody use is not currently
indicated for this condition. COVID-19 illness is a clinical syndrome caused by a SARS-CoV …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

The potential for antibody-based COVID-19 treatments received significant attention early
during the pandemic. As COVID-19 vaccines have been developed, approved and …

There are several approved treatments for coronavirus disease 2019 (COVID-19) in
hospitalized patients but few for patients who are not sick enough to be hospitalized …